Pharma: clinic roundup
Friday, December 13, 2013
Mallinckrodt Inc., of St. Louis, said the Phase III trial of MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, met the primary efficacy endpoint of change in pain from baseline over 48 hours compared to placebo in managing moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.